Linde vs Luxfer
LIN and LXFR side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LIN and LXFR compare
Linde is the larger company, worth 514 times as much as Luxfer ($237B against $461M).
On earnings, Linde is cheaper: it trades at 34.1× trailing earnings, against 57.4× for Luxfer.
Linde grew revenue faster over the last twelve months (8.2% versus −10.6% for Luxfer).
Linde keeps more of each dollar of sales as profit, with a net margin of 19.3% compared with 2.2% at Luxfer.
Both pay dividends: Linde yields 1.2% and Luxfer 2.3%.
Linde scores higher on the StockData Score (16 against 11 for Luxfer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LIN | LXFR |
|---|---|---|
| Size and price | ||
| Market cap | $237B | $461M |
| Share price | $514.24 | $17.23 |
| Change, 1 year | 19.0% | 33.6% |
| Change, 5 years | 54.9% | −21.8% |
| Beta (5Y) | 0.59 | 0.83 |
| Employees | 65K | 1,350 |
| StockData Score | ||
| Total score | 16 (better) | 11 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 5 (better) | 2 |
| Health score | 3 | 6 (better) |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 34.1× (better) | 57.4× |
| P/S | 6.5× | 1.3× (better) |
| P/B | 6.0× | 2.1× (better) |
| EV/EBITDA | 20.1× (better) | 22.4× |
| P/FCF | 46.7× | 27.4× (better) |
| PEG | 1.62 | – |
| FCF yield | 2.1% | 3.6% (better) |
| Fair value | $376.08 | $8.58 |
| Margin of safety | −36.7% (better) | −101% |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | −10.6% |
| Revenue growth, 5Y average | 4.5% (better) | 3.4% |
| Net income growth (TTM) | −1.2% (better) | −67.1% |
| EPS growth (TTM) | 0.87% (better) | −66.7% |
| EPS growth, 5Y average | 25.4% (better) | −17.2% |
| Profitability | ||
| Gross margin | 47.9% (better) | 24.8% |
| Operating margin | 25.3% (better) | 6.3% |
| Net margin | 19.3% (better) | 2.2% |
| FCF margin | 14.0% (better) | 4.6% |
| Return on equity | 18.0% (better) | 3.5% |
| Return on invested capital | 11.5% (better) | 4.7% |
| Financial health | ||
| Debt / equity | 0.68 | 0.26 (better) |
| Net debt / EBITDA | 1.75 (better) | 2.06 |
| Interest coverage | 35.5× (better) | 7.3× |
| Current ratio | 0.86 | 2.33 (better) |
| Altman Z-score | 4.06 (better) | 3.49 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 2.3% (better) |
| Payout ratio | 41.6% | 173% |
| Years of dividend growth | 9 | – |
| Dividend growth, 5Y average | 9.3% | – |
| Buyback yield | 1.7% (better) | 0.74% |
| Shareholder yield | 2.9% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 85.3% | 93.0% |
| Held by insiders | 0.20% | 2.0% |
| Insider net buying, 12 months | −$11.8M | −$322K (better) |
| Superinvestors holding | 6 | – |
| Short interest, % of float | 1.3% | 1.8% |
Go deeper
- LIN stock overview
- LIN income statement
- LIN valuation and score
- LXFR stock overview
- LXFR income statement
- LXFR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.